The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model.

The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. Oncotarget. 2018 Sep 18;9(73):33844-33852 Authors: Mizukami T, Kamachi H, Fujii Y, Matsuzawa F, Einama T, Kawamata F, Kobayashi N, Hatanaka Y, Taketomi A Abstract Pancreatic cancer often has a very poor prognosis, even after complete resection. The recurrence of hepatic and peritoneal metastases is an important prognostic factor; therefore, the development of improved adjuvant therapy is urgently required. Mesothelin is a cell surface glycoprotein whose expression is restricted to a variety of cancer types, including pancreatic cancer. This expression pattern makes mesothelin an attractive target for cancer therapy, and several agents targeting mesothelin are currently in clinical trials. Here, we used the chimerized high-affinity anti-mesothelin monoclonal antibody amatuximab to investigate its effect on peritoneal metastasis. We used the AsPC-1 pancreatic cancer cell line engineered to express Gaussia luciferase (Gluc), (AsPC-1-Gluc) for in vivo experiments. Results showed that while amatuximab was not directly cytotoxic on an AsPC-1-Gluc tumor cells in a peritoneal metastasis model, it prevented the formation of tumor growth. In combination therapy with gemcitabine, amatuximab exhibited synergistic killing. Our results suggest that blockade of mesothelin by am...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

ConclusionsThe adverse events of mFOLFOX6-bevacizumab or CapeOX-bevacizumab in combination with ip PTX were considered similar to those described in previous studies of oxaliplatin-based treatment alone. 1 year after the start of chemotherapy, the efficacy of ip PTX will be evaluated as a secondary outcome.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
AbstractData on the effectivness of PIPAC in patients with peritoneal metastases of pancreaticobiliary origin is scarce. We here present further proof of treatment efficacy in this subset of patients. Repetitive PIPAC treatment with low-dose cisplatin 7.5  mg/m2 and doxorubicin 1.5  mg/m2 body surface area every 6 weeks and prospective data collection. Documentation included microscopic histological regression, median overall survival and treatment-related adverse events. Twelve patients with a median age of 57  years (range 43–78 years) were included. Six patients suffered from pertioneal metasta...
Source: Clinical and Experimental Metastasis - Category: Cancer & Oncology Source Type: research
Introduction: Unresectable pancreatic cancer is one of the unfavorable prognosis cancers with merely one year of median overall survival (OS). Furthermore, the prognosis becomes even worse with peritoneal metastases due to reduced delivery capacity of anti-cancer drugs and lots of associated complications. Recently, the efficacy and safety data of intraperitoneal paclitaxel (ip PTX) in combination with systemic chemotherapy for gastric cancer with peritoneal metastases has been published by Ishigami at the ASCO 2016. We have participated in this intraperitoneal chemotherapy study projects and here we applied this strategy ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Objectives The only cure for pancreatic cancer is surgery. However, some 20% of patients are unexpectedly unresectable due to liver or peritoneal metastases or locally advanced disease which was not predicted by the routinely performed contrast-enhanced CT scan. This means those patients had an unnecessary operation with its associated morbidity and mortality, which also reduces the quality of life and increases health care costs. This raises the question whether image based analysis techniques could help to predict resectability.
Source: Pancreatology - Category: Gastroenterology Authors: Tags: Session 5. Pancreatic Cancer: predispositions and diagnostic advances - free papers Source Type: research
CONCLUSIONS: Cytoreductive surgery with HIPEC may be considered a treatment option in highly selected patients with pancreatic cancer and peritoneal carcinomatosis. PMID: 29745096 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
We report a case in which combination therapy with albumin-bound paclitaxel (nab-paclitaxel) and gemcitabine converted unresectable pancreatic cancer with peritoneal metastases into resectable disease. The patient was a 71-year-old woman with anorexia. Enhanced abdominal computed tomography (CT) showed an atrophic pancreatic body and tail, dilated main pancreatic duct, peritoneal dissemination, portal vein stricture, bile duct stricture and wall thickening, and blockage of the right ureter. She was diagnosed with pancreatic cancer with peritoneal metastases. Curative resection was initially impossible. Combination therapy ...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Ascites is the pathological accumulation of fluid within the abdominal cavity. The most common cancers associated with ascites are adenocarcinomas of the ovary, breast, colon, stomach and pancreas. Symptoms include abdominal distension, nausea, vomiting, early satiety, dyspnea, lower extremity edema, weight gain and reduced mobility. There are many potential causes of ascites in cancer patients, including peritoneal carcinomatosis, malignant obstruction of draining lymphatics, portal vein thrombosis, elevated portal venous pressure from cirrhosis, congestive heart failure, constrictive pericarditis, nephrotic syndrome and ...
Source: Annals of Saudi Medicine - Category: General Medicine Tags: ISSUE 5 Source Type: research
Source: Clinical and Experimental Metastasis - Category: Cancer & Oncology Source Type: research
Conclusion: 89Zr-DFO-HuMab-5B1 PET/CT imaging with HuMab-5B1 is safe and demonstrates promising results for the detection of CA 19-9 positive malignancies. Further studies correlating imaging findings with histopathology are warranted to assess the accuracy of this imaging modality for detection of CA19-9 positive malignancies. Research Support: The clinical study was funded partly by the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center. $$graphic_85017D82-A209-4243-A374-D23F153E67F1$$
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: New Clinical Concepts and First-in-Human Source Type: research
Endoscopy DOI: 10.1055/s-0043-109021For pancreatic solid lesions, ESGE recommends performing endoscopic ultrasound (EUS)-guided sampling as first-line procedure when a pathological diagnosis is required. Alternatively, percutaneous sampling may be considered in metastatic disease.Strong recommendation, moderate quality evidence.In the case of negative or inconclusive results and a high degree of suspicion of malignant disease, ESGE suggests re-evaluating the pathology slides, repeating EUS-guided sampling, or surgery.Weak recommendation, low quality evidence.In patients with chronic pancreatitis associated with a pancreati...
Source: Endoscopy - Category: Gastroenterology Authors: Tags: Guideline Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Pancreas | Pancreatic Cancer | Peritoneal Cancer